Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Autohome

Monolithic Power Systems

Synopsys

According to the All-in-One Screener, a Premium feature of GuruFocus, four companies that have high profitability, business predictability and free cash flow growth are Autohome Inc. (NYSE:ATHM), Masimo Corp. (NASDAQ:MASI), Monolithic Power Systems Inc. (NASDAQ:MPWR) and Synopsis Inc. (NASDAQ:SNPS).

4 Profitable and Predictable Companies With High Free Cash Flow Growth

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo provides a variety of innovative monitoring solutions designed to improve maternal and newborn safety, including SET® pulse oximetry.

Masimo Monitoring Solutions Promote Newborn and Maternal Safety

Abbott Labs

Johnson & Johnson

Medtronic

These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.

4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization

Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.

Masimo's (MASI) Rad-G with Temperature Receives CE Marking

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo Rad-G™ with Temperature, a rugged handheld device with SET® pulse oximetry, respiration rate, and temperature measurement, received CE marking.

Masimo Announces CE Marking of the Rad-G™ with Temperature

Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q4

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 3:50 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops

Masimo to Present in Raymond James 42nd Annual Institutional Investors Conference

Masimo Corporation's (MASI) CEO Joe Kiani on Q4 2020 Results - Earnings Call Transcript

Shares of Masimo (NASDAQ:MASI) fell  in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 7.69% year over year to $0.98, which beat the estimate of $0.86.

Recap: Masimo Q4 Earnings

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended January 2, 2021. Fourth Quarter 2020 Results: Total revenue for the fourth quarter of 2020, including royalty and other revenue, increased 19.2% to $295.1 million, compared to $247.5 million in the fourth quarter of 2019. Product revenue increased 19.2% to $295.1 million, or 18.1% on a constant currency basis, compared to $247.4 million in the fourth quarter of

Masimo Reports Fourth Quarter and Full-Year 2020 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Masimo softFlow®, innovative high-flow nasal cannula therapy, is now available in the U.S. for spontaneously breathing adult patients.

Masimo Announces U.S. Release of softFlow® High-Flow Nasal Cannula Therapy

Masimo Corporation (MASI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Masimo Corporation (MASI) This Earnings Season?

Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.

Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN

IRVINE, Calif.--(BUSINESS WIRE)--As previously announced on January 13, Masimo (NASDAQ: MASI) will release fourth quarter and full year 2020 financial results for the period ended January 2, 2021, after the market closes on Tuesday, February 23, 2021. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the c

Masimo to Report Fourth Quarter and Full Year 2020 Financial Results after Market Close on Tuesday, February 23

IRVINE, Calif.--(BUSINESS WIRE)--Masimo SafetyNet-OPEN™, a web and mobile app solution that helps organizations stay open safely during COVID-19 and beyond, has full market release.

Masimo Announces Full Market Release of Masimo SafetyNet-OPEN™

Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.

Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the BTIG MedTech and Digital Health Conference on Thursday, February 18, 2021 at 11:00 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a

Masimo to Present in BTIG MedTech and Digital Health Conference

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Masimo (MASI)

IRVINE, Calif.--(BUSINESS WIRE)--Masimo has successfully completed the acquisition of LiDCO, a leading provider of advanced hemodynamic monitoring systems.

Masimo Expands Suite of Advanced Measurements Through Acquisition of UK-Based LiDCO Group Plc

Annexon, Inc

ASA Gold and Precious Metals Ltd

Blackrock Health Sciences Trust

BlackRock Health Sciences Trust II

BlackRock Science & Technology

BlackRock Science and Technology Trust II

Genmab - ADR

Kymera Therapeutics

Oak Street Health

Seagen

Sigilon Therapeutics

Taysha Gene Therapies

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments.

BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential

Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.

Masimo's (MASI) iSirona to Boost Hospital Automation Platform

IRVINE, Calif.--(BUSINESS WIRE)--Masimo announced iSirona™, a compact, versatile, connectivity hub that routes data from medical devices to the Masimo Hospital Automation™ platform.

Masimo Announces the iSirona™ Connectivity Hub

Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.

Masimo (MASI) Reports Encouraging 2020 Preliminary Results

AMN Healthcare Services

Royal Philips

R1 RCM Inc

The booming digital health space has been witnessing significant M&A activities amid the pandemic.

Digital Health M&As Gain Precedence in the New Normal

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 2, 2021 and provided estimates for its full-year 2021 financial guidance. Preliminary Full-Year 2020 Results: Masimo expects that its product revenue for the full-year 2020 will range from $1.139 billion to $1.144 billion, which reflects reported growth of 21.6% to 22.2% and constant currency growth of 21.6% to 22.1%, respectivel

News for Masimo Stock (MASI)